Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neurotoxicity Syndromes 2Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Paresthesia 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Diseases 1Anemia 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

entinostat 4exemestane 3Trastuzumab 2Docetaxel 2Cyclophosphamide 2ribociclib 1pembrolizumab 1pegfilgrastim 1ipatasertib 1gadoterate meglumine 1dactolisib 1atezolizumab 1Zoledronic Acid 1Trabectedin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sodium Chloride 1Paclitaxel 1Leflunomide 1Ibuprofen 1High-Energy Shock Waves 1Fulvestrant 1Fentanyl 1Exercise 1Everolimus 1Erlotinib Hydrochloride 1Educational Status 1Doxorubicin 1Codeine 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Diseases × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡